Hydrocephalus is defined as an imbalance between the production and absorption of CSF. This increase in CSF may be due to numerous reasons such as defective absorption, over production of CSF, brain atrophy, or obstruction of circulation. The additional CSF is stored in subarachnoid spaces of the brain or within the ventricles. This condition is also termed as hydrodynamic CSF disorder. Hydrocephalus majorly occurs in babies during birth. It also occurs in elderly people. If hydrocephalus happens in a newborn, it can physically deform the child as CSF continues to build up, causes the child’s head to expand to accommodate the excessive CSF. However, unlike an older child or adult, the infant head is able to expand since their fontanels are not yet closed. If hydrocephalus is left untreated, it can lead to mental retardation due to extreme pressure being exerted on surrounding cerebral tissue causing the brain to atrophy. Higher rates of neural tube defects and neonatal infection in emerging countries are related to advanced rates of hydrocephalus. Around 1% to 2% of the population of the U.S. was affected by hydrocephalus and over 350,000 procedures were performed to treat hydrocephalus in the country in 2014. Moreover, in Canada, one in every 1547 people suffers from hydrocephalus.
Read Full Report: http://www.transparencymarketresearch.com/csf-management-market.html
Based on type of product, the CSF management market has been classified into CSF shunts and CSF drainage systems. CSF drainage system has been further classified into ventricular drainage system and lumbar drainage system. The CSF shunts segment held the largest market share of the CSF management market in 2014. The segment is likely to continue to dominate the market during the forecast period. However, the CSF drainage systems segment is projected to expand at the highest growth rate during the forecast period. The overall rise in incidence of neurological diseases among the general population, increasing geriatric population diagnosed with neurological disease such as Alzheimer’s and Parkinson’s diseases, high funding by the government and private organizations, and growing demand for minimally invasive surgeries are likely to drive the CSF management market. However, risk of infection during the time of surgery is expected to limit the usage of CSF shunts.
Geographically, the CSF management market has been segmented into North America, Europe, Asia-Pacific, Latin America, and Rest of the World. North America accounted for the largest share of the CSF management market in 2014. The region is likely to continue its dominance of the market during the forecast period due to increasing geriatric population and rapid technological innovations. However, the CSF management market in Asia-Pacific is anticipated to witness the fastest growth rate from 2015 to 2023 due to increasing demand for minimally invasive surgeries, rise in the geriatric population, and growing medical tourism in emerging nations. However, factors such as cost of surgical procedures and availability of shunts in developing countries can hinder the growth of the CSF management market.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2590
Economic development and improving health care infrastructure in emerging economies such as China, India, and Brazil have led to increase in disposable income of people, thereby enhancing their purchasing power. In addition, increase in medical expenditure by governments creates an opportunity in the CSF management market in emerging countries.
Major players in the CSF Management Market consist of DePuy Synthes (a J & J Company), Medtronic plc, B. Braun Melsungen AG, Sophysa S.A., Spiegelberg GmbH & Co. KG, Integra LifeSciences Holding Corporation, BeckerSmith Medical, Inc., and Moller Medical GmbH.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453